299 related articles for article (PubMed ID: 8348503)
1. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder.
Carballido JA; Moltó LM; Manzano L; Olivier C; Salmerón OJ; Alvarez de Mon M
Cancer; 1993 Sep; 72(5):1743-8. PubMed ID: 8348503
[TBL] [Abstract][Full Text] [Related]
2. Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer.
Moltó L; Alvarez-Mon M; Carballido J; Olivier C; Gimeno F; Manzano L
Cancer; 1995 Jun; 75(11):2720-6. PubMed ID: 7743476
[TBL] [Abstract][Full Text] [Related]
3. Thymostimulin enhances the natural cytotoxic activity of patients with transitional cell carcinoma of the bladder.
Moltó LM; Carballido JA; Manzano L; Olivier C; Lapuerta M; Alvarez-Mon M
Int J Immunopharmacol; 1993 Apr; 15(3):335-41. PubMed ID: 8505146
[TBL] [Abstract][Full Text] [Related]
4. Interferon beta enhances the natural killer activity of patients with bladder carcinoma.
Moltó L; Carballido J; Manzano L; Olivier C; Lapeña P; Alvarez-Mon M
Cancer Immunol Immunother; 1994 Jun; 38(6):406-10. PubMed ID: 8205562
[TBL] [Abstract][Full Text] [Related]
5. Keyhole limpet hemocyanine can enhance the natural killer activity of patients with transitional cell carcinoma of the bladder.
Moltó LM; Carballido J; Jurincic C; Lapeña P; Manzano L; Salmerón I; Klippel KF; Alvarez-Mon M
Eur Urol; 1991; 19(1):74-8. PubMed ID: 2007423
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory effect of interferon-alpha 2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladder.
Alvarez-Mon M; Moltó LM; Manzano L; Olivier C; Carballido JA
Anticancer Drugs; 1992 May; 3 Suppl 1():5-8. PubMed ID: 1611117
[TBL] [Abstract][Full Text] [Related]
7. T lymphocytes infiltrating the bladder wall of patients with carcinoma of urinary bladder are in vivo activated.
Reyes E; Carballido J; Prieto A; Molto L; Manzano L; Alvarez-Mon M
Eur Urol; 1997; 31(4):472-7. PubMed ID: 9187910
[TBL] [Abstract][Full Text] [Related]
8. Natural killer (NK) cell assay within bladder mucosa of patients bearing transitional cell carcinoma (TCC) after interferon (IFN) therapy: an immunohistochemical and ultrastructural study.
Natsis K; Toliou T; Stravoravdi P; Kirtsis P; Grekou A; Barich A; Konstantinidis E; Gigis P
Int J Clin Pharmacol Res; 1997; 17(1):31-6. PubMed ID: 9403351
[TBL] [Abstract][Full Text] [Related]
9. Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro.
Liu W; O'Donnell MA; Chen X; Han R; Luo Y
Cancer Immunol Immunother; 2009 Oct; 58(10):1647-55. PubMed ID: 19214503
[TBL] [Abstract][Full Text] [Related]
10. Disease-related lymphocyte cytotoxicity in rats bearing transitional cell carcinoma of bladder. Effect of immunomodulators.
Moroz C; Madgar I; Twig S; Lindner A; Many M
Int J Cancer; 1982 Jun; 29(6):667-72. PubMed ID: 6980847
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the effect of intravesical treatment with interferon-alpha 2b on the clinical evolution and on the in vivo function of T lymphocytes and natural killer cells in patients with superficial bladder tumors.
Carballido J; Moltó LM; Olivier C; Manzano L; Alvarez-Mon M
Anticancer Drugs; 1992 May; 3 Suppl 1():9-12. PubMed ID: 1611118
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation.
Suttmann H; Jacobsen M; Reiss K; Jocham D; Böhle A; Brandau S
J Urol; 2004 Oct; 172(4 Pt 1):1490-5. PubMed ID: 15371877
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 2 and interferon alpha modulation of the lymphocyte non-major histocompatibility-restricted lytic activity in glioblastoma patients.
Lapeña P; Isasi C; Moltó L; Martínez R; Vaquero J; Alvarez-Mon M
Int J Immunopharmacol; 1992 Nov; 14(8):1307-13. PubMed ID: 1464464
[TBL] [Abstract][Full Text] [Related]
14. Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon.
Böhle A; Thanhäuser A; Ulmer AJ; Ernst M; Flad HD; Jocham D
J Urol; 1993 Dec; 150(6):1932-7. PubMed ID: 8230540
[TBL] [Abstract][Full Text] [Related]
15. Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation.
Molto L; Alvarez-Mon M; Carballido J; Manzano L; Guillen C; Prieto A; Olivier C; Rodriguez-Zapata M
Br J Cancer; 1994 Dec; 70(6):1247-51. PubMed ID: 7981084
[TBL] [Abstract][Full Text] [Related]
16. Immunocompetence of tissue infiltrating lymphocytes in bladder tumors.
Tsujihashi H; Matsuda H; Uejima S; Akiyama T; Kurita T
J Urol; 1988 Oct; 140(4):890-4. PubMed ID: 3262173
[TBL] [Abstract][Full Text] [Related]
17. Dysfunction of natural killer cells in patients with transitional cell carcinoma.
Lin CT; Yu MT; Li C; Ho YC; Shen CH; Liu DW; Chang DC; Wu SF
Cancer Lett; 2010 May; 291(1):39-45. PubMed ID: 19931980
[TBL] [Abstract][Full Text] [Related]
18. Effects of maximal exercise on natural killer (NK) cell cytotoxicity and responsiveness to interferon-alpha in the young and old.
Woods JA; Evans JK; Wolters BW; Ceddia MA; McAuley E
J Gerontol A Biol Sci Med Sci; 1998 Nov; 53(6):B430-7. PubMed ID: 9823739
[TBL] [Abstract][Full Text] [Related]
19. Activation by the protein-bound polysaccharide PSK (krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer.
Mizutani Y; Yoshida O
J Urol; 1991 May; 145(5):1082-7. PubMed ID: 2016797
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity in vitro of blood lymphocytes from bladder cancer patients and controls to allogeneic or autologous tumor cells derived from established cell lines or short-term cultures.
Troye M; Vilien M; Pape GR; Perlmann P
Int J Cancer; 1980 Jan; 25(1):33-43. PubMed ID: 7399743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
